Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
|
US |
|
Lupin Ltd
NSE:LUPIN
|
IN |
|
Prada SpA
F:PRP
|
IT |
|
E
|
Exemplar REITail Ltd
JSE:EXP
|
ZA |
|
Akeso Inc
HKEX:9926
|
CN |
|
Westone Information Industry Inc
SZSE:002268
|
CN |
|
Q
|
Quantum-Si Inc
NASDAQ:QSI
|
US |
Crescent Biopharma Inc (Pre-Reincorporation)
Crescent Biopharma Inc (Pre-Reincorporation) is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The firm is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Crescent Biopharma Inc (Pre-Reincorporation) is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The firm is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
